Avicanna Inc · TSX:AVCN
Avicanna — Investor Presentation (September 2023)
26 slides from Avicanna's investor presentation, Sep 6, 2023
Slide 1: An International Biopharmaceutical Strategy
Q3 2023 An International Biopharmaceutical Strategy For Naturally Derived and Evidenced Based Products TSX: AVCN OTCQX: AVCNF FSE: 0NN avicanna.com © 2023 Avicanna Inc.
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain statements contained in this presentation, other than statements of fact that are independently veri able at the date hereof, may constitute “forward-looking statements” within the meaning of Canadian securities legislation and regulations and other applicable secu
Slide 3: Timeline
0.1 Timeline Avicanna is a commercial and scale-up stage biopharmaceutical company established in R&D, and commercialization of evidence-based cannabinoid products for the international consumer, medical and pharmaceutical market segments. Supported by its Canadian scientific platform, Avicanna has
Slide 4: Corporate highlights
0.2 Corporate highlights An international medical and biopharmaceutical strategy Scientific platform • Established R&D and clinical platform • Partnerships with leading academic and clinical institutions • JLABS @Johnson and Johnson incubated – at MaRS • Pharmaceutical pipeline Commercial platform •
Slide 5: Avicanna's Five Business Pillars
0.3 Avicanna’s Five Business Pillars Intellectual Property and Brands Owned by Avicanna Medical Cannabis and Pharmaceutical Pipeline Medical Cannabis Wellness Products In Development and Pharmacy Platform Commercial Registration Stages Commercial Cosmetics and Active Skincare Pharmaceutical Commerci
Slide 6: Scientific Platform
1. Scienti c Platform R&D Platform Delivering Advanced and Evidence-Based Cannabinoid Products © 2023 Avicanna Inc. fi
Slide 7: Established Scientific Platform
1.1 Established Scienti c Platform 30+ 10+ Proprietary Scientists Commercial Products R&D through several Health 7 Canada issued Cannabis Pending Patents Research Licenses 11 Commercial Stage Canadian Government Advanced Drug Delivery Research Grants Systems Products Awarded Since 2020 07 © 2023 Avi
Slide 8: World-Class Institutional Collaborations
1.2 World-Class Institutional Collaborations 20+ R&D, Pre-Clinical Studies and Collaborations with Canada’s Leading Institutions since 2017 08 © 2023 Avicanna Inc. 
Slide 9: Commercial Products & Pipeline
2. Commercial Products & Pipeline Serving the Global Marketplace with Proprietary Advanced Cannabinoid-Based Products © 2023 Avicanna Inc.
Slide 10: RHO Phyto
Transdermal Gel Capsules Water-Soluble Tablets Infusers Local Creams Sublingual 2.1 RHO Phyto Oil Spray Drops Advanced Drug Delivery System Formulations (CBD, THC, CBG) - for International Medical and Wellness Market Segments © 2023 Avicanna Inc.
Slide 11: RHO Phyto and Medical Cannabis
2.1.1 RHO Phyto and Medical Cannabis Advanced Drug Evidence-based with Long-term Stability Accurate Dosing Advanced Pre-clinical & Accurate & Easy Delivery Platforms Pre-clinical Data & Consistency & Easy to Use Delivery Clinical Studies Consistent Dosing to Use • Successful proof of concept with ma
Slide 12: Canadian Commercialization Infrastructure
2.1.2 Canadian Commercialization Infrastructure 118 Commercial Listings Across Medical and Retail Channels Canadian Commercialization Infrastructure National Medical Channels Provincial Retail Channels 26 7 National Medical Cannabis Proprietary Commercial SKUs Portals O ering Avicanna Across 4 Brand
Slide 13: Proof of Concept and Partnership with Medical Cannabis by Shoppers
2.1.3 Succesful Proof of Concept and Partnership with Medical Cannabis by Shoppers Avicanna X Medical Cannabis by Shoppers Partnership, since 2019 • 23 commercial SKUs across 4 brands, strategic commercial and clinical partnership • Successful segmentation medical patients and aging population Natio
Slide 14: Introducing MyMedi.ca
2.2.1 Introducing MyMedi.ca Established Through Acquisition from Medical Cannabis by Shoppers • Transition From Medical Cannabis by Shopper’s Drug Mart Platform • Evidence-Driven Medical Cannabis Marketplace and Online Pharmacy • Pharmacist-Led and Bilingual Patient Support Programs and Customer Ser
Slide 15: MyMedi.ca Portfolio and Brands
2.2.2 MyMedi.ca Portfolio and Brands 200+ SKUs from 12 Licensed Producers 15 © 2023 Avicanna Inc. 
Slide 16: MyMedi.ca Highlights
2.2.3 MyMedi.ca Highlights • 19,428 Active Patients • Those Between 40-69 Years of Age Make Up 60% of the Total Patient Group • Although Insurance Coverage Only Makes Up 10.5% of the Patient Pool, These Patients Make Up for Nearly 65% of the Total Sales • Weekly We See Between 400-500 New Medical Do
Slide 17: Medical Cannabis Education and Training
2.2.4 Medical Cannabis Education and Training A federally-registered Canadian non-pro t A resource for health care professionals that are organization of basic and clinical researchers, health interested in learning more about the use and care professionals and educators that promote prescription of
Slide 18: Pharmaceutical Pipeline and Drug Candidates
2.3.1 Pharmaceutical Pipeline and Drug Candidates Designed to Address 5 Major Clinical Areas Sleep Eczema/ Pain Anxiety & Epilepsy Epidermolysis Management Depression Bullosa • Candidates are in various stages of R&D, pre-clinical to real world evidence studies and or registration stage • Leveraging
Slide 19: Trunerox 10% CBD
2.3.2 TruneroxTM 10% CBD (100 mg/ml Cannabidiol) Pharmaceutical Drug Preparation Pending Market Authorization • Pharmaceutical preparation under GMP standards with proprietary formulation with enhanced absorption • Expected marketing authorization during late 2023/ early 2024 several South American
Slide 20: Pura H&W: Clinically Backed CBD Dermacosmetic Products
2.4 Pura H&W: Clinically Backed CBD Dermacosmetic Products Functional Skin Care Products Addressing Global Emerging CBD Consumer Product Segment • Proprietary and patent-pending line of 13 premium topical products • Clinically backed first line of CBD topical products supported by clinical results (
Slide 21: Aureus Santa Marta: Cannabinoids and Standardized Genetics
2.5 Aureus Santa Marta: Cannabinoids and Standardized Genetics Avicanna’s Supply Chain Business Unit and Vertical Integration Raw Material Business Unit Branded as Aureus Santa Marta • Avicanna’s low cost and consistent supply of cannabinoids for its finished products through in-house cultivation an
Slide 22: Avicanna Around the World
2.6 Avicanna Around the World Completed Sales and Exports into 19 Countries MyMedi.ca MEDICAL CANNABIS CARE 22 © 2023 Avicanna Inc. 
Slide 23: Financial & Capital Overview
3. Financial & Capital Overview Highlights • Common shares: 87M* • Tightly held by insiders and strategic investors • 200% Revenue growth between Q1-2023 to Q2 2023 TSX: AVCN R&D and Pharmaceutical issuer on the TSX senior exchange since IPO in 2019 OTCQX: FSE: AVCNF 0NN *As of close of market Septe
Slide 24: Management and Board of Directors
3.1 Management and Board of Directors Senior Management Team Board of Directors Aras Azadian Aras Azadian Founder and CEO Founder and CEO Phillip Cardella Eileen McCormack Chief Financial O cer Independant Director Stephen Kim John McVicar Chief Legal O cer & General Counsel Independant Director Iva
Slide 25: Corporate Highlights
3.2 Corporate Highlights De-risked investment - commercial stage, with key regulatory approvals and milestones achieved, with several product lines Diversified - scalable and high margin revenue streams Experienced management - proven track record since 2016 Intellectual property powerhouse - indust
Slide 26: Thank You
THANK YOU © 2023 Avicanna Inc.